Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease
Journal of Thrombosis and Haemostasis · 2025-02 · 23 (2) · 531-545
DOI: 10.1016/j.jtha.2024.09.030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-02. Verfasst von Luisa Weiss und 13 weiteren Autor:innen. Beteiligte Einrichtung: UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, Univer…. Hauptthemen laut MEDLINE: Rivaroxaban, Aspirin, Cardiovascular Diseases, Extracellular Vesicles. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer AG, Science Foundation Ireland.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland; AI for Healthcare Hub, Institute…
- Health Research Board Clinical Research Facility Galway, School of Medicine, University of Galway, Galway, Ireland.
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland.
- UCD Conway SPHERE Research Group, Conway Institute, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
- Mass Spectrometry Core, Systems Biology Ireland, University College Dublin, Dublin, Ireland.
- Flow Cytometry Core, Conway Institute, University College Dublin, Dublin, Ireland.
Förderung
- Bayer AG
- Science Foundation Ireland
Zitieren
APA
Weiss, L., O'Doherty, A., Uhrig, W., Szklanna, P. B., Hong-Minh, M., Wynne, K., Blanco, A., Zivny, J., Lima Passos, V., Kevane, B., Murphy, S., Ní Áinle, F., O'Donnell, M., & Maguire, P. B. (2025). Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease. Journal of Thrombosis and Haemostasis, 23(2), 531-545. https://doi.org/10.1016/j.jtha.2024.09.030
Vancouver
Weiss L, O'Doherty A, Uhrig W, Szklanna PB, Hong-Minh M, Wynne K, et al. Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease. Journal of Thrombosis and Haemostasis. 2025;23(2):531-545. doi:10.1016/j.jtha.2024.09.030
BibTeX
@article{Weiss2025,
author = {Weiss, Luisa and O'Doherty, Aideen and Uhrig, Wido and Szklanna, Paulina B and Hong-Minh, Molly and Wynne, Kieran and Blanco, Alfonso and Zivny, Jan and Lima Passos, Valeria and Kevane, Barry and Murphy, Seán and Ní Áinle, Fionnuala and O'Donnell, Martin and Maguire, Patricia B},
title = {Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {2},
pages = {531--545},
doi = {10.1016/j.jtha.2024.09.030}
}
EUVIMED